The Scale of Chronic Pain and Why the Opioid Crisis Changed Drug Development

Chronic pain affects an estimated 100 million Americans and represents the leading source of disability globally, generating annual economic losses exceeding $560–635 billion. This burden — combined with the public health catastrophe of opioid dependence — has fundamentally redirected analgesic drug development away from opioid-receptor agonism and toward peripherally acting, mechanistically distinct targets that carry no addiction liability.

Patent activity across the retrieved dataset — spanning filings from 2009 to 2025 — maps this shift precisely. Chronic pain is uniformly characterised in retrieved records as pain persisting beyond the natural healing timeline of the causative injury or disease, serving no protective function. Primary indication targets cited across filings include chronic low back pain (CLBP), osteoarthritis (OA) pain, cancer-related bone pain, diabetic peripheral neuropathy pain (DPNP), and opioid-induced hyperalgesia (OIH).

The opioid addiction-avoidance framing is not merely rhetorical: at least three assignees in the patent dataset — Regeneron Pharmaceuticals, Rinat Neuroscience (now Pfizer), and H. Lundbeck A/S — explicitly position their programs around averting opioid dependence in chronic pain patients. According to WHO, opioid dependence affects tens of millions worldwide, and the regulatory environment in major markets increasingly rewards non-opioid analgesic mechanisms with expedited pathways and favourable labelling.

The Dominant Molecular Targets: CGRP, NGF/TrkA, and NaV1.7

Three molecular axes account for the majority of patent-dense activity in this dataset: the NGF/TrkA receptor system, calcitonin gene-related peptide (CGRP), and the NaV1.7 voltage-gated sodium channel. Each is supported by distinct mechanistic and, in the case of NaV1.7, human genetic validation.

NGF/TrkA: The Most Patent-Dense Target

Nerve growth factor (NGF) and its high-affinity receptor TrkA are the most frequently cited mechanistic targets in the retrieved dataset. Retrieved filings describe NGF as a key sensitiser of nociceptive neurons, with TrkA activation amplifying chronic pain signalling through dorsal root ganglia (DRG) primary sensory neurons. Multiple assignees — including Pfizer, Regeneron, Abbott Research B.V., PanGenetics B.V., MedImmune, Rinat Neuroscience, and AlderBio Holdings — have filed patents claiming anti-NGF antibodies that inhibit NGF/TrkA binding. Blocking this interaction prevents sensitisation of DRG nociceptors and attenuates hyperalgesia and allodynia in inflammatory and neuropathic pain models. Human genetic data citing TrkA mutations in hereditary sensory and autonomic neuropathy type IV and NGF mutations in type V is referenced in Regeneron filings as target validation evidence.

CGRP: Peripheral Nociception and Vasodilation

CGRP is a 37-amino acid neuropeptide co-released with substance P from primary sensory neurons into the spinal cord. Retrieved Pfizer and Teva filings specify peripheral (systemic) administration targeting CGRP to avoid CNS side effects. Pfizer Ireland Pharmaceuticals has additionally pursued intranasal formulation to address delivery challenges in migraine patients with nausea. The dataset identifies approximately 15 or more anti-CGRP antibody patent filings, with geographic prosecution spanning WO, EP, CA, NZ, IL, JP, HK, IN, and AU jurisdictions — scope consistent with programs that reached advanced international prosecution stages. According to FDA records, several CGRP-targeting agents have received regulatory approval for migraine prevention, validating the target commercially.

NaV1.7: Genetically Validated, Mechanistically Complex

NaV1.7 is a peripherally restricted voltage-gated sodium channel expressed in DRG sensory neurons that gates nociceptive signal propagation. Loss-of-function NaV1.7 mutations are associated with congenital pain insensitivity in humans, as cited in retrieved UCL Business PLC patent filings. UCL’s filings further highlight that NaV1.7 knockout mice show elevated Met- and Leu-enkephalin levels, and that intravenous naloxone reversal of the pain-free state in human subjects with NaV1.7 loss-of-function mutations constitutes a human proof-of-concept for the NaV1.7/enkephalin axis. This underpins the mechanistic rationale for combining NaV1.7 inhibitors with enkephalinase inhibitors or low-dose opioids.

“NaV1.7 loss-of-function mutations produce a pain-free state sustained by elevated endogenous enkephalins — naloxone reversal of this state in human subjects constitutes direct proof-of-concept for the NaV1.7/opioid axis as a non-addictive analgesic target.”

A separate approach to NaV1.7, disclosed by the Arizona Board of Regents on behalf of the University of Arizona, avoids direct channel pore blockade entirely. Instead, a CRMP2-derived peptide containing the amino acid sequence KMD blocks NaV1.7 trafficking to the cell surface via SUMOylation of CRMP2 — an indirect mechanism framed as an alternative to address selectivity challenges across NaV subtypes.

Pipeline Modalities: From Antibodies to Nucleic Acid Drugs

The chronic pain pipeline is not monolithic. Retrieved patent records span four distinct therapeutic modality classes — monoclonal antibodies, small molecules, nucleic acid drugs, and combination biologics — each targeting the pain signalling cascade at a different node.

Anti-CGRP and Anti-NGF Monoclonal Antibodies

Anti-CGRP antibodies represent the largest cluster of retrieved patents, with approximately 15 or more filings. These biologics bind CGRP ligand or receptor and block pro-nociceptive and vasodilatory signalling. Retrieved patents describe peripheral administration as the intended route, with specific CDR sequences disclosed for chronic pain indications including bone cancer pain, migraine, and drug overuse headache. Anti-NGF antibodies constitute an equally dense cluster, with AlderBio filings specifically distinguishing p75-selective versus dual p75/TrkA blockade as a mechanistic differentiator.

Anti-PACAP Antibodies: The Newest Biologic Frontier

PACAP (pituitary adenylate cyclase-activating polypeptide) is cited across multiple filings as a contributor to spinal sensitisation, opioid withdrawal anxiety, and migraine. H. Lundbeck A/S filings from 2024–2025 represent the most recent activity in the dataset and describe anti-PACAP antibodies that bind human PACAP and antagonise vasodilation, mast cell degranulation, and neuronal activation. Lundbeck’s data specifically demonstrates anti-PACAP antibody efficacy in morphine-treated animal models of OIH and chronic migraine, with the claim that administration provided “full attenuation of opioid-induced pain.” Alder Biopharmaceuticals (subsequently acquired by Lundbeck) filed earlier anti-PACAP compositions in 2018 across CN and JP jurisdictions.

Novel Small Molecules and Non-Biologic Mechanisms

Several retrieved results describe non-antibody, non-opioid modalities that address different points in pain chronification. The University of California (Regents) discloses NAAA (N-acylethanolamine acid amidase) inhibitors — specifically ARN19702 and ARN16186 — that halt the transition from acute to chronic pain by stimulating mitochondrial respiration. A 3-day regimen was shown to normalise sensory responses, anxiety-like behaviour, and neuroimaging measures including spinal and forebrain diffusion tensor imaging (DTI) measures in rodent chronic pain-like state models — an endpoint consistent with IND-enabling preclinical work. According to research indexed by NIH, NAAA-mediated pathways modulate palmitoylethanolamide signalling, a mechanism with established anti-inflammatory and analgesic properties.

Medicor Pharmaceuticals describes sulindac phosphate for central sensitisation-related pain and diabetic peripheral neuropathy pain, distinguished from classic NSAIDs by NF-κB inhibition that operates independently of COX-1/COX-2. Fraunhofer-Gesellschaft describes CYP2J2 antagonists for chemotherapy-induced peripheral neuropathic pain, with combination TRPV1 agonist use also proposed. West China Hospital of Sichuan University discloses siRNA/shRNA drugs silencing the NALCN sodium leak channel, delivered via liposomes, cationic polymer micelles, or adeno-associated virus (AAV), with claimed efficacy in neuropathic and inflammatory pain.

An additional small-molecule signal comes from a retrieved Chinese patent (Baierhewen Pharmaceutical Co.) that lists specific approved or late-stage CGRP small-molecule receptor antagonists by name: ubrogepant, rimegepant, atogepant, olcegepant, telcagepant, and vazegepant — confirming that CGRP small-molecule antagonism has reached late-stage or marketed status in this indication space, as documented in regulatory databases maintained by agencies including EMA.

Combination and Bispecific Strategies Signal a Maturing Field

Recent patent filings from 2020 to 2025 show a decisive shift toward multi-target engagement, signalling that single-target monotherapy may be approaching commercial saturation in the CGRP and NGF spaces. Seven distinct combination or bispecific strategies are identifiable in the retrieved dataset.

The most mechanistically novel is the UCL Business PLC approach: pharmaceutical compositions combining a selective NaV1.7 inhibitor with an opioid analgesic or enkephalinase inhibitor. The rationale is grounded in human genetics — NaV1.7 loss-of-function mutations produce a pain-free state sustained by elevated endogenous enkephalins, and naloxone reversal of this state in human subjects establishes the endogenous opioid contribution. This creates a synergistic, mechanistically rationalized non-addictive combination strategy filed across WO (2015) and EP (2016) jurisdictions.

MedImmune Limited (AstraZeneca) has filed patents for chimeric NGF antagonist / TNFα antagonist domain fusion proteins, claiming synergistic analgesia beyond either monotherapy in chronic nociceptive pain models. Amgen has separately filed a bispecific antigen-binding protein simultaneously blocking the CGRP receptor and PAC1 receptor — targeting two distinct pro-nociceptive neuropeptide axes in a single molecule for chronic pain, migraine, and cluster headache. Allergan Pharmaceuticals International Limited (WO 2021) signals a combination of CGRP pathway blockade with botulinum toxin-mediated peripheral neurotransmitter suppression for inflammatory and neurologic pain disorders.

“Combination and bispecific strategies are increasingly prevalent in filings from 2020–2025, signalling that single-target monotherapy may be approaching commercial saturation in CGRP and NGF spaces, with innovation shifting toward multi-target engagement.”

A further combination signal comes from Baierhewen Pharmaceutical (CN 2021), which describes “breakthrough” CGRP antagonist gepants administered to patients already on biologic CGRP antibody prophylaxis — a combination that could expand treatment utility for breakthrough pain episodes. Apkarian Technologies LLC (WO/CA/US 2020) discloses D1/D2 dopaminergic agonists at low dose ratios combined with analgesics to prevent acute-to-chronic pain transition, leveraging cortical pain processing pathways. Allergan’s TLR4 antagonist approach — using dextro enantiomers of naltrexone, naloxone, and nalmefene to act through glial TLR4 rather than classical opioid receptors — represents a mechanistically distinct non-addictive strategy that does not engage the conventional opioid receptor system.

IP Landscape: Assignee Concentration and White Space

Patent activity in this dataset is predominantly driven by large pharmaceutical and mid-size biotech organisations, with academic institutions contributing primarily preclinical mechanistic filings. The assignee landscape reveals both areas of high concentration and genuine strategic white space.

High-Concentration Areas

Pfizer is the highest-volume single assignee in the dataset, with filings spanning anti-CGRP antibodies for chronic pain (2009–2019, multiple jurisdictions), anti-NGF antibodies for CLBP (2020, WO/CA/US), and CGRP inhibitor intranasal formulations (2022, IL). Teva Pharmaceuticals International GmbH holds multiple anti-CGRP antibody filings for chronic pain (2009–2019, AU, EP, IL, JP), including drug overuse headache extensions. Regeneron Pharmaceuticals has filed its anti-NGF antibody program across AU, CA, EP, JP, MY, NZ, PH, SG, US, and WO jurisdictions (2018–2024), with explicit opioid addiction-avoidance positioning. New entrants face substantial freedom-to-operate challenges in the CGRP and NGF/TrkA spaces unless pursuing differentiated formats such as bispecifics, novel epitopes, or formulation innovations.

The WIPO patent cooperation treaty (PCT) filing geography across retrieved records — spanning WO, EP, US, CA, AU, JP, CN, IL, IN, NZ, HK, MY, PH, SG — indicates that the major assignees have pursued broad international prosecution, leaving limited geographic white space in core CGRP and NGF territories.

Emerging White Space

PACAP/PAC1 receptor antagonism is underrepresented in competing assignee activity within the dataset, with Lundbeck’s multi-jurisdiction 2024–2025 filings indicating early prosecution of a next-generation biologics program for OIH. NaV1.7 indirect approaches — specifically CRMP2 peptide-mediated trafficking interference and enkephalinase-based co-administration — may offer superior selectivity profiles compared to direct channel pore blockade, representing potential IP white space. Academic filings from the University of California (NAAA inhibitors), University of Notre Dame (HDAC inhibitor triple formulation), and West China Hospital of Sichuan University (NALCN siRNA/shRNA) cover mechanisms with limited large-pharma patent density, suggesting licensing or co-development opportunities.

Eli Lilly and Company appears in the dataset with an anti-TGF-α / epiregulin bispecific antibody for OA pain, DPNP, and CLBP (CA, JP, 2021–2023) — a mechanistically distinct biologic approach that does not overlap with the dominant CGRP/NGF filings. University of Connecticut/YADAV filings (WO 2023) describe non-opioid pain relief via full-length recombinant PRG4 protein or fragments acting through TNF-α inhibition, representing a further non-overlapping mechanism. For R&D teams and IP strategists navigating this landscape, PatSnap’s IP intelligence platform provides freedom-to-operate analysis and white space mapping across all major jurisdictions.